Navigation Links
CardioVascular BioTherapeutics, Inc. Funding Wound Healing Trial with R&D Partnership

LAS VEGAS, April 24 /PRNewswire-FirstCall/ -- CardioVascular BioTherapeutics, Inc. (OTC Bulletin Board: CVBTE) has entered into an agreement with Mr. Phillip Frey Jr. to form Cardio Derma Clinical Partners (CDCP), an R&D Partnership. Mr. Frey, as sponsor and general partner, will fund a minimum of $1,000,000 and up to $5,000,000 of the clinical development of CVBT's wound healing drug candidate.

"R&D Partnerships have been successfully used in the past by some of today's biggest names in biotechnology to fund drug development. Many investors in these R&D Partnerships realized income tax advantages and have earned outstanding returns on their investments," said Mr. Phillip Frey Jr. He continued, "CVBT and Cardio Derma Clinical Partners are going back to these basics in an effort to advance this drug candidate."

CDCP will engage CVBT in a development agreement to conduct its wound healing clinical trial. CVBT will pay a royalty to CDCP of 10% of revenues or other moneys received from the commercialization of the drug candidate up to a maximum of ten times (10x) the funded amount of the development agreement in return for the intellectual property created. Additionally, CDCP will acquire warrants, the number of which is dependent upon the funded amount of the development agreement, to purchase CVBT common shares at an exercise price of $1.00 per share with a term of five years. Daniel C. Montano, CVBT's President and CEO, has agreed to personally provide the individual partners of CDCP a Put to Mr. Montano for their interest in CDCP equal to 200% of their investment in CDCP less distributions paid from CDCP commencing 36 months and ending 60 months after their investment in CDCP.

CVBT's pipeline includes drug candidates for the treatment of various cardiovascular diseases, including severe coronary heart disease, diabetic wounds, peripheral arterial disease, chronic back pain and bone repair. "We anticipate knowing whether we will meet the endpoints of the Phase II coronary heart disease and wound healing trials in approximately 12 to 18 months," said Mr. Montano. He continued, "Conducting FDA clinical trials is expensive and requires timely access to capital. The disruptions in the financial market over the last six months have made access to capital more difficult. Given the current market, we believe that structuring R&D Partnerships tailored to the circumstances of individual drug candidates and partnerships provides a sensible financing alternative for funding our clinical trials."

According to Mickael A. Flaa, CVBT's Chief Financial Officer, "The ability to attract capital in this form is a major milestone in the financial growth and maturity of CVBT." Mr. Flaa continued, "This financing vehicle is very attractive to both the Company and its shareholders due to assumption of risk of loss by the R&D Partnership and the modest dilution resulting from the financing. The R&D Partnership concept is the type of financing alternative that CVBT will focus on for other drug candidates in the pipeline until the financial markets are receptive to timely, cost effective access to capital for CVBT common stock."

About Mr. Phillip Frey Jr.

Mr. Phillip Frey Jr. is the retired Chairman, CEO, and President of Microsemi Corporation (MSCC). He was Chairman of Microsemi's Board of Directors from 1986 through 2002 and a member of the Board of Directors since 1973. He also served as its President and CEO from 1971 to December 2000. Microsemi Corporation designs, manufactures, and markets analog and mixed-signal integrated circuits (ICs) and semiconductors. Since retiring from Microsemi Corporation, Mr. Frey has focused his business endeavors in real estate investments and has been a major angel investor in numerous new ventures in the medical and electronics areas.

About CardioVascular BioTherapeutics

CVBT is a biopharmaceutical company developing human FGF-1 for cardiovascular diseases characterized by inadequate blood flow to a tissue or organ. In addition to the Phase II trial it is conducting in patients with severe coronary heart disease, the company has two FDA-authorized clinical trials in the areas of impaired wound healing seen in diabetes and in patients suffering from peripheral artery disease of the legs. An additional proof-of-concept study is being conducted in patients with chronic back pain who may have perfusion defects to their spine. For more information please visit

This news release contains forward-looking statements that involve risks and uncertainties. Actual results and outcomes may differ materially from those discussed or anticipated. For example, statements regarding expectations for new research, progress with clinical trials or future business initiatives are forward looking statements. Factors that might affect actual outcomes include, but are not limited to, FDA approval of CVBT drug candidates, market acceptance of CVBT products by customers, new developments in the industry, future revenues, future expenses, future margins, cash usage and financial performance. For a more detailed discussion of these and associated risks, see the company's most recent documents filed with the Securities and Exchange Commission.

Media Contact:

Allison Lipson

CardioVascular BioTherapeutics, Inc.

(702) 839-7200

SOURCE CardioVascular BioTherapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. CardioVascular BioTherapeutics, Inc. Announces Update on Timing of Form 10-K Filing
3. Significant Reductions in Mortality and Cardiovascular Events Shown Using Blood Pressure-Lowering Treatment in Those Aged 80 and Over
4. HealthAware Introduces Its VascularAware Cardiovascular Disease Module
5. GlaxoSmithKline Responds to JAMA Article on the ICES Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes
6. VIA Pharmaceuticals Expands Clinical Advisory Board With Leading Experts in Cardiovascular Disease
7. VIA Pharmaceuticals Lead Compound, VIA-2291, Chosen as a Top Ten Most Licensable Cardiovascular Program for Windhover Informations Therapeutic Area Partnerships Conference
8. Amarin Announces Initiation of Cardiovascular Development Strategy
9. NFL Hall of Fame Legend Fred Biletnikoff Joins AFL/Signalife Cardiovascular Protection Team
10. Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology
11. Legendary Earvin Magic Johnson Joins AFL/Signalife Cardiovascular Protection Team
Post Your Comments:
(Date:11/25/2015)... Studies reveal the differences in species of ... way for more effective treatment for one of the most ... --> --> Gum disease is ... yet relatively little was understood about the bacteria associated with ... by researchers from the WALTHAM Centre for Pet Nutrition together ...
(Date:11/25/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; TSX: ... prospects remain fundamentally strong and highlights the following ... received DSMB recommendation to continue the ZoptEC Phase ... the final interim efficacy and safety data ... men with heavily pretreated castration- and Taxane-resistant prostate ...
(Date:11/25/2015)... November 25, 2015 The ... is a professional and in-depth study on the ...      (Logo: ) , ... industry including definitions, classifications, applications and industry chain ... the international markets including development trends, competitive landscape ...
(Date:11/24/2015)... ... November 24, 2015 , ... The United States Golf Association (USGA) today ... Green Section Award. Presented annually since 1961, the USGA Green Section Award recognizes an ... turfgrass. , Clarke, of Iselin, N.J., is an extension specialist of turfgrass ...
Breaking Biology Technology:
(Date:10/27/2015)... 27, 2015 In the present market scenario, ... for various industry verticals such as banking, healthcare, defense, ... growing demand for secure & simplified access control and ... as hacking of bank accounts, misuse of users, , ... as PC,s, laptops, and smartphones are expected to provide ...
(Date:10/27/2015)... SAN JOSE, Calif. , Oct. 27, 2015 /PRNewswire/ ... human interface solutions, today announced that Google has adopted ... family of touch controller solutions to power its newest ... Nexus 6P by Huawei. --> ... ecosystem partners like Google to provide strategic collaboration in ...
(Date:10/26/2015)... and LAS VEGAS , Oct. ... Labs , an innovator in modern authentication and a ... announced the launch of its latest version of the ... enabling organizations to use standards-based authentication that supports existing ... S3 Authentication Suite is ideal for organizations deploying customer-facing ...
Breaking Biology News(10 mins):